BR0110877A - Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer - Google Patents
Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncerInfo
- Publication number
- BR0110877A BR0110877A BR0110877-8A BR0110877A BR0110877A BR 0110877 A BR0110877 A BR 0110877A BR 0110877 A BR0110877 A BR 0110877A BR 0110877 A BR0110877 A BR 0110877A
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- increasing
- topoisomerase inhibitor
- dosage
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODOS DE TRATAMENTO DE CâNCER PRIMáRIO DE AUMENTO DA DOSAGEM DE UM INIBIDOR DE TOPOISOMERASE, DE REDUçãO OU PREVENçãO DE UM EFEITO ADVERSO ASSOCIADO COM QUIMIOTERAPIA E COM TERAPIA DE RADIAçãO, DE AUMENTO DA EFICáCIA TERAPêUTICA DE UM INIBIDOR DE TOPOISOMERASE, E DE PROTEçãO DE UM PACIENTE CANCEROSO DOS EFEITOS ADVERSOS ASSOCIADOS COM A ADMINISTRAçãO DE UMA DROGA ANTI-CâNCER, COMPOSIçãO FARMACêUTICA, FORMA DE DOSAGEM, E, KIT PARA USO NO TRATAMENTO DE CâNCER". Esta invenção refere-se às composições compreendendo talidomida e outra droga anti-câncer que podem ser usadas no tratamento ou na prevenção do câncer. Drogas anti-câncer preferias são inibidores de topoisomerase. Uma composição particular compreende talidomida ou um sal, clatrato ou solvato farmaceuticamente aceitável da mesma, e irinotecano. A invenção também se refere aos métodos de tratamento ou prevenção do câncer que compreendem a administração de uma talidomida ou outra droga anti-câncer a um paciente necessitando de um tal tratamento ou de uma tal prevenção. A invenção refere-se em adição aos métodos de redução ou de evitação dos efeitos colaterais adversos associados com a administração de quimioterapia ou de terapia de radiação que compreendem a administração de talidomida a um paciente necessitando de tal redução ou evitação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20414300P | 2000-05-15 | 2000-05-15 | |
PCT/US2001/015327 WO2001087307A2 (en) | 2000-05-15 | 2001-05-10 | Compositions and methods for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0110877A true BR0110877A (pt) | 2003-03-11 |
Family
ID=22756804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0110877-8A BR0110877A (pt) | 2000-05-15 | 2001-05-10 | Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer |
Country Status (19)
Country | Link |
---|---|
US (2) | US7435726B2 (pt) |
EP (1) | EP1307197B1 (pt) |
JP (1) | JP5409981B2 (pt) |
KR (1) | KR100790589B1 (pt) |
AR (1) | AR029084A1 (pt) |
AT (1) | ATE322266T1 (pt) |
AU (2) | AU2001261474B2 (pt) |
BR (1) | BR0110877A (pt) |
CA (1) | CA2408707C (pt) |
DE (1) | DE60118571T2 (pt) |
DK (1) | DK1307197T3 (pt) |
ES (1) | ES2258084T3 (pt) |
HK (1) | HK1054502A1 (pt) |
MX (1) | MXPA02011218A (pt) |
NZ (1) | NZ522767A (pt) |
PT (1) | PT1307197E (pt) |
TW (1) | TWI289449B (pt) |
WO (1) | WO2001087307A2 (pt) |
ZA (1) | ZA200209638B (pt) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192360A1 (en) * | 1999-04-14 | 2005-09-01 | Li Chiang J. | Method of treatment of pancreatic cancer |
ATE374609T1 (de) * | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
US6440738B1 (en) * | 2001-02-08 | 2002-08-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of casein kinase 2-beta expression |
AU2002249103A1 (en) * | 2001-03-29 | 2002-10-15 | Topo Target Aps | Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors |
IL160960A0 (en) * | 2001-09-24 | 2004-08-31 | Tosk Inc | Reduced toxicity cisplatin formulations and methods for using the same |
US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
PT2305255E (pt) * | 2001-12-03 | 2012-09-04 | Bayer Healthcare Llc | Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos |
WO2003051382A1 (fr) * | 2001-12-14 | 2003-06-26 | Sundory Co., Ltd. | Procédé d'induction d'apoptose et compositions pour cette dernière |
US20050171036A1 (en) * | 2002-03-26 | 2005-08-04 | Banyu Pharmaceutical Co., Ltd. | Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination |
CN1705439A (zh) * | 2002-04-12 | 2005-12-07 | 细胞基因公司 | 干细胞和祖细胞分化的调节、鉴定及其应用 |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
EP1496880A4 (en) * | 2002-04-24 | 2007-12-12 | Res Dev Foundation | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTINEOPLASTIC AGENTS |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
CN1697655B (zh) * | 2002-05-17 | 2013-09-18 | 细胞基因公司 | 使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物 |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
NZ536908A (en) * | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
CA2489947A1 (en) * | 2002-06-24 | 2003-12-31 | Research Development Foundation | Treatment of human multiple myeloma by curcumin |
US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US8404716B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
EP1551385A4 (en) * | 2002-10-15 | 2008-10-22 | Celgene Corp | SELECTIVE CYTOKINE INHIBITOR DRUGS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
MXPA05004780A (es) * | 2002-11-06 | 2005-10-05 | Celgene Corp | Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos. |
NZ540384A (en) * | 2002-11-06 | 2008-06-30 | Celgene Corp | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
WO2004087713A1 (en) * | 2003-03-31 | 2004-10-14 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
CL2004001004A1 (es) * | 2003-05-19 | 2005-03-18 | Upjohn Co | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. |
WO2004113502A2 (en) * | 2003-06-20 | 2004-12-29 | Avalon Pharmaceuticals, Inc. | Identification of therapeutic agents using genetic fingerprinting |
US7264819B2 (en) * | 2003-06-23 | 2007-09-04 | Anticancer, Inc. | Lyase treatment for P. carinii |
US20050049299A1 (en) * | 2003-08-26 | 2005-03-03 | Aggarwal Bharat B. | Selective inhibitors of stat-3 activation and uses thereof |
WO2006046934A2 (en) | 2003-08-26 | 2006-05-04 | Research Development Foundation | Osteoclastogenesis inhibitors and uses thereof |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
EA200600921A1 (ru) * | 2003-11-06 | 2006-10-27 | Селджин Корпорейшн | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний |
NZ548049A (en) * | 2003-12-02 | 2009-01-31 | Celgene Corp | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
ATE427943T1 (de) * | 2003-12-12 | 2009-04-15 | Quiral Quimica Do Brasil | Verfahren zur herstellung von wasserfreien und hydratisierten pharmazeutischen wirkstoffen (apis); aus diesen hergestellte stabile pharmazeutische zusammensetzungen und anwendungen fur diese zusammensetzungen |
EP1722777A2 (en) * | 2004-02-20 | 2006-11-22 | Arqule, Inc. | Use of beta-lapachone for the treatment of pancreatic cancer |
EP1729760A2 (en) * | 2004-02-20 | 2006-12-13 | Arqule, Inc. | Use of beta-lapachone for the treatment of lung cancer |
CA2555941A1 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for treatment of colon cancer |
JP2007523956A (ja) * | 2004-02-25 | 2007-08-23 | ダナ−ファーバー キャンサー インスティテュート インク. | 腫瘍細胞増殖を阻害するための方法 |
US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
LT2574341T (lt) | 2004-03-29 | 2017-09-11 | University Of South Florida | Navikų ir vėžio efektyvus gydymas triciribino fosfatu |
US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
US20100173864A1 (en) * | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
JP2007532642A (ja) * | 2004-04-14 | 2007-11-15 | セルジーン・コーポレーション | 脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物 |
BRPI0418742A (pt) * | 2004-04-14 | 2007-09-11 | Celgene Corp | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit |
RU2408387C2 (ru) * | 2004-04-27 | 2011-01-10 | Веллстат Байолоджикс Корпорейшн | Лечение злокачественного новообразования с применением вирусов и камптотецинов |
CN1984652A (zh) * | 2004-05-05 | 2007-06-20 | 细胞基因公司 | 使用选择性细胞因子抑制药治疗和控制骨髓增生性疾病的方法和组合物 |
CN1984651A (zh) * | 2004-05-05 | 2007-06-20 | 细胞基因公司 | 使用选择性细胞因子抑制药治疗和控制癌症和其它疾病的方法和组合物 |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
NZ564954A (en) * | 2005-06-14 | 2011-02-25 | Protox Therapeutics Inc | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
CA2640598A1 (en) * | 2006-02-03 | 2007-08-09 | Noboru Yamazaki | Liposome preparation |
US20100021519A1 (en) * | 2006-04-27 | 2010-01-28 | Narmada Shenoy | Compositions and Methods for Treating or Preventing Diseases of Body Passageways |
CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
US7893045B2 (en) | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
US20100311683A1 (en) * | 2007-11-01 | 2010-12-09 | Beach C L | Cytidine analogs for treatment of myelodysplastic syndromes |
SI2219451T1 (sl) * | 2007-11-21 | 2015-02-27 | Oxigene, Inc. | Postopek za zdravljenje hematopoetskih neoplazem |
US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
CA2751892A1 (en) | 2009-01-15 | 2010-07-22 | Rutgers, The State University Of New Jersey | Benzo [c] phenanthridines as antimicrobial agents |
WO2010127307A1 (en) | 2009-04-30 | 2010-11-04 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
CA2810162A1 (en) | 2010-06-09 | 2011-12-15 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
US9102617B2 (en) | 2010-06-25 | 2015-08-11 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
AU2011352036A1 (en) | 2010-12-31 | 2013-07-18 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
KR101369936B1 (ko) * | 2011-12-28 | 2014-03-06 | 연세대학교 산학협력단 | 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물 |
US9822108B2 (en) | 2012-01-13 | 2017-11-21 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
WO2013142712A1 (en) | 2012-03-21 | 2013-09-26 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
WO2014180882A2 (en) * | 2013-05-07 | 2014-11-13 | Universitat De Barcelona | Treatment of brain metastasis from cancer |
US20170080093A1 (en) * | 2013-10-22 | 2017-03-23 | Tyme, Inc. | Tyrosine Derivatives And Compositions Comprising Them |
US9458150B2 (en) | 2013-11-08 | 2016-10-04 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
RS64038B1 (sr) | 2014-08-22 | 2023-04-28 | Celgene Corp | Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima |
SI3313818T1 (sl) | 2015-06-26 | 2024-03-29 | Celgene Corporation | Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev |
US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
US10513528B2 (en) | 2016-02-25 | 2019-12-24 | Taxis Pharmaceuticals, Inc. | Synthetic processes and intermediates |
BR112019001398A2 (pt) | 2016-07-29 | 2019-05-07 | Janssen Pharmaceutica Nv | métodos para tratamento de câncer de próstata |
KR101851470B1 (ko) | 2016-12-19 | 2018-06-11 | 한림대학교 산학협력단 | 퀘세틴이 함유된 유방암 예방 및 치료를 위한 약제학적 조성물 |
CN110891566B (zh) | 2017-03-30 | 2023-12-19 | 塔克西斯医药股份有限公司 | 合成方法和合成中间体 |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US5422344A (en) * | 1990-05-08 | 1995-06-06 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Method of treating retroviral infections in mammals |
WO1992014455A1 (en) | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5654312A (en) | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
GB9523493D0 (en) * | 1995-11-16 | 1996-01-17 | British Biotech Pharm | Preparation of allyl succinate derivatives and starting materials therefore |
-
2001
- 2001-05-10 JP JP2001583775A patent/JP5409981B2/ja not_active Expired - Fee Related
- 2001-05-10 BR BR0110877-8A patent/BR0110877A/pt active Search and Examination
- 2001-05-10 PT PT01935373T patent/PT1307197E/pt unknown
- 2001-05-10 AU AU2001261474A patent/AU2001261474B2/en not_active Ceased
- 2001-05-10 ES ES01935373T patent/ES2258084T3/es not_active Expired - Lifetime
- 2001-05-10 WO PCT/US2001/015327 patent/WO2001087307A2/en active IP Right Grant
- 2001-05-10 DE DE60118571T patent/DE60118571T2/de not_active Expired - Lifetime
- 2001-05-10 AU AU6147401A patent/AU6147401A/xx active Pending
- 2001-05-10 AT AT01935373T patent/ATE322266T1/de active
- 2001-05-10 NZ NZ522767A patent/NZ522767A/en not_active IP Right Cessation
- 2001-05-10 EP EP01935373A patent/EP1307197B1/en not_active Expired - Lifetime
- 2001-05-10 DK DK01935373T patent/DK1307197T3/da active
- 2001-05-10 MX MXPA02011218A patent/MXPA02011218A/es active IP Right Grant
- 2001-05-10 CA CA2408707A patent/CA2408707C/en not_active Expired - Fee Related
- 2001-05-10 KR KR1020027015443A patent/KR100790589B1/ko not_active IP Right Cessation
- 2001-05-14 US US09/853,617 patent/US7435726B2/en not_active Expired - Fee Related
- 2001-05-15 AR ARP010102298A patent/AR029084A1/es unknown
- 2001-06-26 TW TW090111620A patent/TWI289449B/zh active
-
2002
- 2002-11-27 ZA ZA200209638A patent/ZA200209638B/en unknown
-
2003
- 2003-08-29 HK HK03106199A patent/HK1054502A1/xx not_active IP Right Cessation
-
2005
- 2005-03-09 US US11/074,849 patent/US20050148524A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1054502A1 (en) | 2003-12-05 |
JP2003533484A (ja) | 2003-11-11 |
AR029084A1 (es) | 2003-06-04 |
DE60118571D1 (de) | 2006-05-18 |
KR20030025922A (ko) | 2003-03-29 |
CA2408707A1 (en) | 2001-11-22 |
US7435726B2 (en) | 2008-10-14 |
US20020035090A1 (en) | 2002-03-21 |
AU2001261474B2 (en) | 2006-03-09 |
AU6147401A (en) | 2001-11-26 |
US20050148524A1 (en) | 2005-07-07 |
TWI289449B (en) | 2007-11-11 |
WO2001087307A2 (en) | 2001-11-22 |
DE60118571T2 (de) | 2007-02-01 |
WO2001087307A3 (en) | 2002-07-25 |
ATE322266T1 (de) | 2006-04-15 |
PT1307197E (pt) | 2006-08-31 |
ZA200209638B (en) | 2003-11-27 |
KR100790589B1 (ko) | 2008-01-02 |
JP5409981B2 (ja) | 2014-02-05 |
DK1307197T3 (da) | 2006-07-03 |
CA2408707C (en) | 2010-04-13 |
EP1307197B1 (en) | 2006-04-05 |
EP1307197A2 (en) | 2003-05-07 |
ES2258084T3 (es) | 2006-08-16 |
NZ522767A (en) | 2004-07-30 |
MXPA02011218A (es) | 2004-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0110877A (pt) | Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer | |
BRPI0406667A (pt) | Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg | |
BR0207024A (pt) | Medicamento com ação inicial rápida para o tratamento de disfunção sexual | |
BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
CR8352A (es) | Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos | |
RS114004A (en) | Modified 2' and 3'-nucleoside produgs for treating flaviridae infections | |
GEP20053595B (en) | Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment | |
BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
CA2442168A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
AU2002305952B2 (en) | Pharmaceutical combinations | |
BRPI0415649A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
WO2007112274A3 (en) | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin | |
WO2001068125A3 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
WO2021168483A3 (en) | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors | |
BRPI0511800A (pt) | tratamento com irinotecano (cpt-11) e um inibidor de egfr | |
AP1780A (en) | Use of cox-2 inhibitors for preventing immunodeficiency. | |
AU2002305952A1 (en) | Pharmaceutical combinations | |
CO5200778A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis | |
KR20020069201A (ko) | 약학 조합제제 | |
CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
BR0214135A (pt) | Produto farmacêutico, dose farmacêutica, usos de um anti-estrogênio e de um inibidor da aromatase e 4'-ciano-alfa', alfa, alfa'-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2- metilpropiono-m-toluidida ou um sal ou solvato farmaceuticamente aceitáveis destes, e, método para tratar de câncer da próstata e/ou reduzir o risco de câncer da próstata em um paciente | |
BR112023002295A2 (pt) | Terapia de combinação | |
MXPA06007510A (es) | Composiciones de farmaco y formas de dosis novedosas de topiramato. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 15A ANUIDADE. |
|
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |